- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02935244
Advanced Understanding of Staphylococcus Aureus Infections in Europe - Surgical Site Infections (ASPIRE-SSI)
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The primary objective of ASPIRE-SSI is to determine the incidence of S. aureus infections, particularly S. aureus SSIs, in various adult surgical patient populations, and to identify the patient-related, pathogen-related, and contextual risk factors for the development of S. aureus SSI. Using this information, a SSI prediction tool will be derived for future clinical trials and public health interventions aimed at SSI prevention. Furthermore, immunologic features protective against S. aureus SSI will also be assessed.
The knowledge obtained by this study will enable identification of the surgical patients most at risk of developing S. aureus infections, particularly S. aureus SSI, and who would probably benefit most from new interventions given prophylactically and specifically to prevent S. aureus infections.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Gent, Bélgica
- Algemeen Ziekenhuis Sint-Lucas & Volkskliniek Gent
-
Lier, Bélgica
- H. Hartziekenhuis
-
-
-
-
-
Brno Střed, Chequia
- St. Anne's University Hospital Brno
-
Nový Hradec Králové, Chequia
- University Hospital Hradec Kralove
-
Ostrava, Chequia
- University Hospital Ostrava
-
Praha, Chequia
- University Hospital Motol
-
-
-
-
-
Barcelona, España
- Hospital Universitari de Bellvitge
-
Cadiz, España
- Hospital Universitari del Mar
-
Córdoba, España
- HU Reina Sophia
-
Oviedo, España
- Hospital Universitario Central de Asturias
-
Sevilla, España
- Hospital Universitario Virgen Macarena
-
-
-
-
-
Tallin, Estonia
- North Estonia Medical Centre
-
Tartu, Estonia
- Tartu University Clinic
-
-
-
-
-
Limoges, Francia
- Centre Hospitalier Universitaire de Limoges
-
-
-
-
-
Ancona, Italia
- Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona
-
Brescia, Italia
- Brescia Hospital
-
Rimini, Italia
- Ospedale Infermi di Rimini
-
-
-
-
-
Assen, Países Bajos
- Wilhemina Ziekenhuis Assen
-
Breda, Países Bajos
- Amphia Hospital
-
Utrecht, Países Bajos
- UMC Utrecht
-
-
-
-
-
Birmingham, Reino Unido
- Queen Elizabeth Hospital
-
Brighton, Reino Unido
- Brighton & Sussex University Hospital NHS Trust
-
Derby, Reino Unido
- Derby Teaching Hospitals NHS Foundation Trust
-
Manchester, Reino Unido
- The Pennine Acute Hospitals NHS Trust Manchester
-
Middlesbrough, Reino Unido
- South Tees Hospitals NHS Foundation Trust
-
York, Reino Unido
- York Teaching Hospitals NHS Foundation Trust
-
-
-
-
-
Bukarest, Rumania
- Carol Davila University of Medicine and Pharmacy Bucharest
-
Bukarest, Rumania
- Elias University Emergency Hospital
-
Bukarest, Rumania
- Prof. C.C. Iliescu Cardiovascular Diseases Institute
-
Timişoara, Rumania
- Clinic County Hospital Timisoara
-
-
-
-
-
Belgrad, Serbia
- Clinical Centre of Serbia
-
Belgrad, Serbia
- Institute for Orthopedic Surgery Banjica
-
Kragujevac, Serbia
- Clinical Centre of Kragujevac
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients undergoing 1 of the protocol-defined surgical procedures are eligible for inclusion in the study. However, enrolment in the study cohort population will be based on preoperative S. aureus colonization. In total, approximately 3300 S. aureus colonized subjects and 1700 non-colonized subjects will be enrolled in the study cohort population.
Protocol-defined surgical procedures: Coronary artery bypass grafting; ICD implantation; knee and hip prosthesis surgery; laminectomy and spinal fusion surgery; emergency surgery; central artery reconstructive and peripheral artery bypass surgery; mastectomy; and craniotomy.
Descripción
Inclusion Criteria:
- The subject is 18 years of age or older.
- The subject is undergoing 1 of the protocol-defined surgical procedures. The surgical procedure is planned or unplanned.
- The subject has been screened for S. aureus colonization from three body regions: nose, throat, and perineum within 30 days prior to surgery, and based on the preoperative S. aureus colonization status of the subject, the subject qualifies for enrolment in the study cohort.
- Written informed consent has been obtained prior to enrollment in the study cohort.
Exclusion criteria:
- Parallel participation in any experimental study of an anti-Staphylococcus preventive intervention.
- An active diagnosis of a SSI as the reason for surgery.
- Not able to comply with study procedures and follow-up based on Investigator judgment.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Incidence of S. aureus SSI
Periodo de tiempo: Up to 90 days following surgery.
|
Up to 90 days following surgery.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Incidence of serious S. aureus SSI (deep and organ/space S. aureus SSI)
Periodo de tiempo: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Incidence of S. aureus bloodstream infection
Periodo de tiempo: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Incidence of other post-surgical S. aureus infection
Periodo de tiempo: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Incidence of all-cause SSI, by etiologic agent
Periodo de tiempo: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Incidence of S. aureus SSI stratified by antibiotic susceptibility
Periodo de tiempo: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Prevalence of preoperative S. aureus colonization in nose, throat and perineal region.
Periodo de tiempo: No more than 30 days prior to surgery
|
No more than 30 days prior to surgery
|
|
Incidence of S. aureus SSI stratified by location of preoperative S. aureus colonization
Periodo de tiempo: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Incidence of post-surgical all-cause mortality
Periodo de tiempo: Up to 90 days following surgery
|
Up to 90 days following surgery
|
|
Semi-quantification of the bacterial load of colonizing S. aureus
Periodo de tiempo: At the time of preoperative screening for S. aureus colonization (within 30 days prior to surgery)
|
At the time of preoperative screening for S. aureus colonization (within 30 days prior to surgery)
|
|
Characterization of S. aureus isolates involved in colonization
Periodo de tiempo: At the time of preoperative screening for S. aureus colonization (within 30 days prior to surgery)
|
Clonal type, gene sequence, and expression of certain virulence factors of S. aureus isolates
|
At the time of preoperative screening for S. aureus colonization (within 30 days prior to surgery)
|
Serum antibody levels against S. aureus virulence factors.
Periodo de tiempo: Within 30 days prior to surgery (for the preoperative sample) and 2-6 weeks following the SSI episode (for the post-SSI sample)
|
Within 30 days prior to surgery (for the preoperative sample) and 2-6 weeks following the SSI episode (for the post-SSI sample)
|
|
Characterization of S. aureus isolates involved in infections
Periodo de tiempo: Up to 90 days following surgery
|
Clonal type, gene sequence, and expression of certain virulence factors of S. aureus isolates
|
Up to 90 days following surgery
|
Otras medidas de resultado
Medida de resultado |
Periodo de tiempo |
---|---|
Magnitude of healthcare utilization associated with S. aureus SSI in terms of: a. Duration of length of stay (LOS) b. Incidence of readmissions, including re-interventions due to S. aureus SSI c. Duration of LOS during readmissions
Periodo de tiempo: Up to 90 days following surgery
|
Up to 90 days following surgery
|
Incidence of S. aureus SSI, stratified by participating country
Periodo de tiempo: Up to 90 days following surgery
|
Up to 90 days following surgery
|
Incidence of S. aureus SSI, stratified by type of surgery
Periodo de tiempo: Up to 90 days following surgery
|
Up to 90 days following surgery
|
Incidence of S. aureus SSI, stratified by wound classification
Periodo de tiempo: Up to 90 days following surgery
|
Up to 90 days following surgery
|
Incidence of S. aureus SSI, stratified by urgency of surgery
Periodo de tiempo: Up to 90 days following surgery
|
Up to 90 days following surgery
|
Incidence of S. aureus SSI, stratified by American Society of Anesthesiologists Physical Score classification
Periodo de tiempo: Up to 90 days following surgery
|
Up to 90 days following surgery
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jan AJW Kluytmans, MD PhD, UMC Utrecht
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Complicaciones Postoperatorias
- Heridas y Lesiones
- Atributos de la enfermedad
- Infecciones bacterianas
- Infecciones bacterianas y micosis
- Infecciones por bacterias grampositivas
- Infecciones
- Enfermedades contagiosas
- Herida quirúrgica
- Infección de herida quirúrgica
- Infección en la herida
- Infecciones estafilocócicas
Otros números de identificación del estudio
- NL57595.041.16
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Estafilococo aureus
-
Ohio State UniversityTerminadoStaphylococcus aureus resistente a la meticilina | Infección por Staphylococcus aureus sensible a la meticilinaEstados Unidos
-
Forest LaboratoriesTerminadoBacteriemia por Staphylococcus aureus | Staphylococcus aureus resistente a la meticilina (MRSA) BacteriemiaEstados Unidos
-
Todd C. Lee MD MPH FIDSAAún no reclutandoBacteriemia por Staphylococcus aureus | Endocarditis por Staphylococcus aureus | Staphylococcus aureus Septicemia | Sepsis estafilocócicaCanadá
-
Menzies School of Health ResearchThe University of Queensland; Australasian Society for Infectious Diseases; Singapore... y otros colaboradoresTerminadoStaphylococcus aureus resistente a la meticilinaAustralia, Nueva Zelanda, Israel, Singapur
-
Intron Biotechnology, Inc.TerminadoVoluntarios Saludables | Agentes antibacterianos | Staphylococcus aureus resistente a la meticilina | Infección por Staphylococcus aureus sensible a la meticilinaCorea, república de
-
University of PennsylvaniaRetiradoBacteriemia por Staphylococcus aureus | Endocarditis por Staphylococcus aureusEstados Unidos
-
University of PennsylvaniaChildren's Hospital of Philadelphia; Milton S. Hershey Medical Center; Pennsylvania...TerminadoMRSA - Infección por Staphylococcus Aureus resistente a la meticilinaEstados Unidos
-
Massachusetts General HospitalTerminadoMRSA - Infección por Staphylococcus Aureus resistente a la meticilinaEstados Unidos
-
University College, LondonKing's College London; Rambam Health Care Campus; University of Melbourne; Menzies... y otros colaboradoresAún no reclutandoSepticemia | Infección por Staphylococcus Aureus | Infección del torrente sanguíneo | Bacteriemia por Staphylococcus aureus | Sepsis bacteriana | Staphylococcus aureus Septicemia | Sepsis por estafilococo
-
Armata Pharmaceuticals, Inc.United States Department of DefenseReclutamientoBacteriemia | Estafilococo aureus | Bacteriemia por Staphylococcus aureus | Bacteriemia por Staphylococcus Aureus | Bacteriemia estafilococoEstados Unidos, Australia